Limited potential of hepatic arterial infusion of irinotecan

FA (Floris) de Jong, RHJ Mathijssen, Jaap Verweij

Research output: Contribution to journalArticleAcademicpeer-review

5 Citations (Scopus)


Intravenously administered irinotecan has gained an important place in the struggle against metastatic and/or irresectable colorectal cancer. In patients with irresectable metastases confined to the liver, hepatic arterial infusion (HAI) of this anti-cancer agent has considered to be an option. Partly based on conducted phase I- and II-studies, here we conclude that irinotecan as single agent HAI therapy has limited potential compared to intravenous administration. From a pharmacokinetic-pharmacodynamic point of view, in particular the long half-life of the active metabolite, SN-38, its use is limited as well. In our view, future clinical implementation of irinotecan as HAI chemotherapy is unrealistic.

Original languageEnglish
Pages (from-to)48-50
Number of pages3
JournalJournal of Chemotherapy
Issue numberSuppl 5
Publication statusPublished - Nov 2004

Research programs

  • EMC MM-03-86-08


Dive into the research topics of 'Limited potential of hepatic arterial infusion of irinotecan'. Together they form a unique fingerprint.

Cite this